Journal Options HIV
Course Directors: Joseph J. Eron, Jr., MD, William G. Powderly, MD, Andrew R. Zolopa, MD
View Collections |
|
|
|
Featured Expert Commentary
Timothy R. Sterling, MD
Professor of Medicine
Division of Infectious Diseases
Vanderbilt University School of Medicine
Nashville, Tennessee
Recent Articles
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
Emery S, Neuhaus JA, Phillips AN, et al, for the SMART Study Group. J Infect Dis. 2008;197:1133-1144. Capsule Summary | Expert Commentary | Abstract | Slides
Hepatotoxicity of Antiretroviral Drugs Is Reduced After Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients.
Labarga P, Soriano V, Vispo ME, et al. J Infect Dis. 2007;196:670-676. Capsule Summary | Expert Commentary | Abstract | Slides
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
Lundgren JD, Babiker A, El-Sadr W, et al, for the SMART Study Group. J Infect Dis. 2008;197:1145-1155. Capsule Summary | Expert Commentary | Abstract | Slides
Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
McComsey GA, Re VL 3rd, O'Riordan M, et al. Clin Infect Dis. 2008;46:1290-1296. Capsule Summary | Expert Commentary | Abstract | Slides
Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003.
Patel P, Hanson DL, Sullivan PS, et al. Ann Intern Med. 2008;148:728-736. Capsule Summary | Expert Commentary | Abstract | Slides
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. J Infect Dis. 2008;197:1006-1010. Capsule Summary | Expert Commentary | Abstract | Slides
Class-sparing regimens for initial treatment of HIV-1 infection.
Riddler SA, Haubrich R, DiRienzo AG, et al. New Engl J Med. 2008;358:2095-2106. Capsule Summary | Expert Commentary | Abstract | Slides
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
Sabin CA, Worm SW, Weber R, et al, for the D:A:D Study Group. Lancet. 2008;371:1417-1426. Capsule Summary | Expert Commentary | Abstract | Slides
Durability and Outcome of Initial Antiretroviral Treatments Received during 2000-2005 by Patients in the Swiss HIV Cohort Study.
Vo TT, Ledergerber B, Keiser O, et al. J Infect Dis. 2008;197:1685-1694. Capsule Summary | Expert Commentary | Abstract | Slides
Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study.
Crum-Cianflone N, Hullsiek KH, Marconi V, et al. AIDS. 2009;23:41-50. Capsule Summary | Expert Commentary | Abstract | Slides
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
Volume 5, Issue 2
Collection
HIV Journal Options – Volume 5, Issue 2
Program Directors: Joseph J. Eron, Jr., MD, William G. Powderly, MD, Andrew R. Zolopa, MD
  
- Keith Henry, MD
- Paul Krogstad, MD
- Kristine Patterson, MD
|
  
- Amanda Peppercorn, MD
- Gerald Pierone, Jr. , MD
- Paul E. Sax, MD
|
 
- Timothy R. Sterling, MD
- Timothy Wilkin, MD, MPH
|
Abstract
Volume 5, Issue 1
Collection
HIV Journal Options – Volume 5, Issue 1
  
- Joseph J. Eron, Jr., MD
- William G. Powderly, MD
- Andrew R. Zolopa, MD
|
Faculty: Ian Frank, MD, P. Richard Harrigan, PhD, Charles B. Hicks, MD, Patrick W.G. Mallon, MB, BCh, FRACP, Michael Mugavero, MD, MHSc, James H. Stein, MD, Babafemi Taiwo, MBBS, Charles van der Horst, MD
Abstract
|